Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study

The Lancet Infectious Diseases
Miguel O'RyanChilean IPV/bOPV study group

Abstract

Bivalent oral poliovirus vaccine (bOPV; types 1 and 3) is expected to replace trivalent OPV (tOPV) globally by April, 2016, preceded by the introduction of at least one dose of inactivated poliovirus vaccine (IPV) in routine immunisation programmes to eliminate vaccine-associated or vaccine-derived poliomyelitis from serotype 2 poliovirus. Because data are needed on sequential IPV-bOPV schedules, we assessed the immunogenicity of two different IPV-bOPV schedules compared with an all-IPV schedule in infants. We did a randomised, controlled, open-label, non-inferiority trial with healthy, full-term (>2·5 kg birthweight) infants aged 8 weeks (± 7 days) at six well-child clinics in Santiago, Chile. We used supplied lists to randomly assign infants (1:1:1) to receive three polio vaccinations (IPV by injection or bOPV as oral drops) at age 8, 16, and 24 weeks in one of three sequential schedules: IPV-bOPV-bOPV, IPV-IPV-bOPV, or IPV-IPV-IPV. We did the randomisation with blocks of 12 stratified by study site. All analyses were done in a masked manner. Co-primary outcomes were non-inferiority of the bOPV-containing schedules compared with the all-IPV schedule for seroconversion (within a 10% margin) and antibody titres (within two-thir...Continue Reading

Associated Clinical Trials

Oct 30, 2018·Arun Kumar Sharma

References

Mar 29, 2011·Journal of Virological Methods·David R KilpatrickOlen Kew
Jan 25, 2014·The Journal of Infectious Diseases·Peter F WrightRoland W Sutter
Oct 16, 2014·The Journal of Infectious Diseases·Lauren R PlattRoland W Sutter
Apr 1, 2015·Future Microbiology·Ananda S BandyopadhyayWalter A Orenstein

❮ Previous
Next ❯

Citations

Sep 1, 2015·The Lancet Infectious Diseases·Beth D Kirkpatrick, Josyf C Mychaleckyj
May 24, 2016·Lancet·Edward P K Parker, Nicholas C Grassly
Apr 28, 2018·PLoS Biology·Michael FamulareGuillaume Chabot-Couture
Jun 3, 2016·The Pediatric Infectious Disease Journal·Sasirekha RamaniMiguel L O'Ryan
Oct 31, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Clea SarnquistYvonne A Maldonado
Dec 5, 2019·The Cochrane Database of Systematic Reviews·Agustín CiapponiAikant Bhatti
Oct 31, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·James T GaensbauerEdwin J Asturias
Oct 31, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ananda S BandyopadhyayChris Gast
Oct 5, 2017·BMC Medicine·Kevin A McCarthyLaina D Mercer
Apr 14, 2021·Human Vaccines & Immunotherapeutics·Ting ZhaoJingsi Yang
Jul 10, 2021·Mucosal Immunology·Ruth I ConnorPeter F Wright
Jul 10, 2021·British Journal of Clinical Pharmacology·Jun GaoFenyang Tang
Nov 3, 2021·PloS One·Nancy GerloffEverardo Vega

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.